The head of the Food and Drug Administration lamented that drug companies may abandon making cheaper versions of high-cost specialty drugs because the market is too hard to penetrate.

FDA Commissioner Scott Gottlieb said during a Wednesday event sponsored by the Atlantic that it is hard for drugs called biosimilars to get covered by drug plans and insurers. A biosimilar is a drug that is similar to a tissue-based drug called a biologic but is usually cheaper.

Recommended Stories

Dr. Oz and FDA chief say biosimilar drug reform will lower prices

Braun unveils bill to force drug middlemen to pass savings to consumers

Industry, patient groups weigh in on Trump’s drug pricing plan